FGF-1 vs KGF-1

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Binds FGFR2b (the KGF receptor), which is exclusively expressed on epithelial cells — providing tissue-specific action without mesenchymal effects. Activates RAS/MAPK and PI3K/Akt to promote keratinocyte proliferation and migration. Extends the anagen phase of the hair growth cycle.

KGF-1 (keratinocyte growth factor 1; FGF-7) is a member of the fibroblast growth factor family that signals exclusively through the FGFR2b splice variant expressed on epithelial cells, where it acts as a potent mitogen and cytoprotective factor for keratinocytes and mucosal epithelial cells; uniquely paracrine in nature, KGF-1 is produced by stromal cells to maintain adjacent epithelial layer integrity and support mucosal healing. KGF-1 activates FGFR2b to drive epithelial cell proliferation, migration, and differentiation, and to protect mucosal surfaces from damage caused by cytotoxic therapies; this cytoprotective mechanism forms the basis of its clinical application in preventing chemotherapy- and radiation-induced breakdown of the gastrointestinal epithelium, where FGFR2b is highly expressed. A landmark randomized controlled trial published in the New England Journal of Medicine (2004) demonstrated that palifermin — recombinant human KGF-1 (Kepivance, Amgen) — significantly reduced the incidence and duration of severe oral mucositis in hematologic malignancy patients undergoing myelotoxic conditioning for stem cell transplant; this pivotal Phase 3 study established the evidence base for FDA approval in 2004. Palifermin (Kepivance) is FDA-approved and requires a prescription for prevention of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy; it is not approved for cosmetic applications, general wound healing, or skin rejuvenation, and the KGF-1 evidence base is specific to chemotherapy-conditioning mucosal protection in oncology settings.